Search the Newsreel

Concentra Group Holdings Parent (CON) Is Up 7.6% After Raising 2026 Guidance And Detailing CEO Succession – Has The Bull Case Changed?

Concentra Group Holdings Parent (CON) recently reported strong Q2 2026 results, raising full-year guidance and reaffirming its dividend. The company also announced a CEO succession plan, with current President and CFO Matt DiCanio set to take over in November 2026. This positive news, coupled …

Concord Enviro posts ₹175.69 cr Q1FY27 loss; appoints new CFO

NeOnc to present phase 2a NEO100 trial results on Tuesday By Investing.com

NeOnc Technologies Holdings Inc. (NASDAQ:NTHI) is set to announce topline results from its phase 2a study of intranasal NEO100 for recurrent IDH1-mutant high-grade glioma on Tuesday, with an investor call scheduled for August 12, 2026. The company reported a net loss of $14.2 million …

Concord New Energy expects H1 profit to fall over 66% on drop in power generation

CGON (CGON) insider plans 50,000-share stock sale after option exercise

CG Oncology, Inc. (CGON) filed a Form 144 indicating an insider's plan to sell 50,000 shares of common stock, valued at $3,770,580.00, on August 10, 2026, following a stock option exercise. The filing also details previous common stock sales by Ambaw Bellete over the …

Treace Medical Concepts (NASDAQ:TMCI) Price Target Raised to $5.00 at Truist Financial

Truist Financial has increased its price target for Treace Medical Concepts (NASDAQ:TMCI) from $4.00 to $5.00, while maintaining a "hold" rating, suggesting a potential upside of 10.13%. Despite this, the broader analyst consensus remains "Reduce" with a target of $5.17. The company recently reported …

Broncus Holding Corporation (2216.HK) stock price, news, quote and history

Concentra Poised to Benefit From AI Data Center Development, RBC Says

Concentra Group (CON) is positioned to benefit from a potential pickup in manufacturing and construc PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

BOCOM International: BeiGene maintains 'Buy' rating with target price raised to HK$276

BOCOM International has maintained its 'Buy' rating for BeiGene, increasing the target price to HK$276. This reflects a positive outlook on the biopharmaceutical company's future performance and valuation.

Analysts Offer Insights on NA Companies: Once Upon a Farm, PBC (OFRM) and Deep Fission (FISN)

Two analysts have offered bullish insights on NA sector companies Once Upon a Farm, PBC (OFRM) and Deep Fission (FISN). Goldman Sachs reiterated a Buy rating on Once Upon a Farm with a $23.40 average price target, while Seaport Global initiated coverage on Deep …

Concentra Group Holdings Parent, Inc. (CON) Hit a 52 Week High, Can the Run Continue?

Concentra Group Holdings Parent, Inc. (CON) recently hit a 52-week high of $35.15, with shares up 8% over the past month and 73.1% year-to-date. This outperformance is driven by a strong record of positive earnings surprises, with the company beating consensus estimates in the …

NEONC TECHNOLOGIES HOLDINGS, INC. Q2 2026: Revenue $0 EPS $(0.58) — 10-Q Summary

NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) reported its Q2 2026 financial results, with revenue of $0 and a net loss of $(14.24M), resulting in a diluted loss per share of $(0.58). Despite the financial loss, the company highlighted significant clinical progress, pipeline expansion for NEO212, …

NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout

NeOnc Technologies Holdings, Inc. announced its financial results for the second quarter ended June 30, 2026, highlighting significant clinical and regulatory advancements for its NEO100 and NEO212 programs. The company confirmed that topline results from its Phase 2a NEO100 study in recurrent IDH1-mutant high-grade …

Concentra to Present at Upcoming Investor Conferences

DALLAS, August 10, 2026--(BUSINESS WIRE)--Concentra Group Holdings Parent, Inc. (NYSE: CON), the nation's largest provider of occupational health services by number of locations, today announced that executive and senior management are scheduled to attend the following upcoming investor conferences: Bank of America Virtual SMID …

Concentra Group Holdings Parent, Inc. Just Recorded A 25% EPS Beat: Here's What Analysts Are Forecasting Next

Concentra Group Holdings Parent, Inc. (NYSE:CON) reported strong second-quarter results, exceeding revenue and EPS expectations. Analysts have increased their earnings per share estimates and raised the consensus price target to US$35.38, indicating increased optimism. Despite a projected slowdown in revenue growth, it is expected …

Kura Oncology publishes preclinical data on ziftomenib in Blood By Investing.com

Kura Oncology has published preclinical data in Blood journal detailing the discovery and development of ziftomenib, a menin inhibitor approved by the FDA in 2025 for adult patients with relapsed or refractory NPM1-mutated acute myeloid leukemia. The research highlights ziftomenib's efficacy across various leukemia …

Kura Oncology publishes study highlighting ziftomenib's unique action and potential in treating acute leukemias.

Kura Oncology announced the publication of a study in the journal Blood detailing the discovery and preclinical development of ziftomenib, an FDA-approved menin inhibitor for relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). The study highlights ziftomenib's potent and selective inhibition of the menin-KMT2A …

NeOnc Technologies (NTHI) raises $20M but warns on going concern

NeOnc Technologies Holdings, Inc. (NTHI) reported a net loss of $23.1 million for the first six months of 2026, alongside an accumulated deficit of $135.8 million, raising substantial doubt about its ability to continue as a going concern. Despite raising approximately $20 million through …

NTHI Stock Price and Chart — NASDAQ:NTHI

This article provides an overview of NeOnc Technologies Holdings, Inc. (NTHI) stock, including its current price, market capitalization, key financial metrics, and analyst forecasts. It highlights the company's status as a clinical-stage biopharmaceutical company developing novel technology for central nervous system diseases. The article …

Dimensional Fund Advisors LP Increases Holdings in Kura Oncology, Inc. $KURA

Dimensional Fund Advisors LP significantly increased its stake in Kura Oncology, Inc. by 32.3% in the first quarter, now holding 1.43 million shares valued at $11.6 million. Other institutions also grew their positions, while an insider sold shares. Analysts maintain a "Moderate Buy" rating …

Hennion & Walsh Asset Management Inc. Grows Stake in Kura Oncology, Inc. $KURA

Hennion & Walsh Asset Management Inc. significantly increased its stake in Kura Oncology (NASDAQ:KURA) by 69.7% in Q2, bringing its total holdings to 568,845 shares valued at $6.24 million. Despite reporting a quarterly loss that beat estimates, revenue fell short, and an insider recently …

Concord New Energy flags sharp interim profit drop on weaker power output

Concord New Energy Sets Board Meeting to Approve Interim Results and Dividend

Pyxis Oncology Inc expected to post a loss of 35 cents a share - Earnings Preview

Pyxis Oncology Inc is projected to report a loss of 35 cents per share, according to an earnings preview. This information suggests an upcoming financial disclosure for the company. The full article is available to subscribers of TradingView.

Truist Securities Adjusts PT on Treace Medical Concepts to $5 From $4, Keeps Hold Rating

Truist Securities has raised its price target for Treace Medical Concepts (TMCI) from $4 to $5, while maintaining a "Hold" rating on the stock. This adjustment comes after Treace Medical Concepts recently increased its earnings guidance for the full-year 2026. The medical technology company …

CONCENTRA GROUP HOLDINGS PARENT INC : RBC RAISES TARGET PRICE TO $42 FROM $36

RBC has increased its target price for CONCENTRA GROUP HOLDINGS PARENT INC (CON.N) to $42 from the previous $36. This updated target reflects an optimistic outlook from RBC regarding the company's future performance.

(CGEM) Movement as an Input in Quant Signal Sets

This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM) using AI models to generate trading strategies. It highlights a strong near-term sentiment possibly leading to a long-term positive bias, with support being tested. The analysis provides specific entry, target, and stop-loss levels for position, momentum …

Concentra Group Holdings Parent (CON) Is Up 7.6% After Raising 2026 Outlook And Announcing CEO Transition

Concentra Group Holdings Parent (CON) saw its stock rise 7.6% after reporting Q2 2026 results, raising its full-year 2026 outlook, affirming a dividend, and announcing a CEO transition effective November 1, 2026. The company now expects revenues between US$2.325 billion and US$2.375 billion and …

Treace Medical Concepts (TMCI) Stock Jumps As Cash Burn Eases But Sales Stall

Treace Medical Concepts (TMCI) saw its stock jump 8.7% despite essentially flat Q2 revenue of US$45.4m and a net loss of US$15.9m. Investors reacted positively to a smaller adjusted EBITDA loss and reduced cash burn, indicating a market preference for financial discipline over top-line …

Citius Oncology Inc (CTOR) Earnings Forecast: Future EPS & Revenue Growth Estimates

Bank of America Securities Reaffirms Their Buy Rating on CG Oncology, Inc. (CGON)

Bank of America Securities reiterated a Buy rating on CG Oncology, Inc. (CGON) with an $88.00 price target. This affirmation follows the company's Q2 earnings report, which showed $1.16 million in revenue and a net profit of $0, a significant improvement from the prior …

Concord Medical Services Holdings Ltd. ADR Revenue Breakdown – FWB:C2C

This article provides a brief overview of Concord Medical Services Holdings Ltd. ADR (FWB:C2C) revenue breakdown, highlighting that its greatest contribution came from China. In the last year, China accounted for 54.54 million EUR, which was an increase from 51.54 million EUR the year …

Once Upon A Farm Q2 Earnings Call Highlights

MarketBeat Week in Review – 02/09 - 02/13 Once Upon A Farm (NYSE:OFRM) reported second-quarter fiscal 2026 net sales growth of 42.3% as distribution gains, product innovation and a national club program supported volume-led expansion across its baby and kid nutrition portfolios. Net sales …

BridgeBio Oncology Therapeutics, Inc. Stock 12‑Month Price Target Cut to $24.89, Implies 167% Upside

BridgeBio Oncology Therapeutics, Inc. (BBOT) has seen its average 12-month price target cut slightly from $25.3 to $24.89 by 9 analysts. This new target still implies a significant 167% potential upside from its August 7th closing price. The consensus rating from 10 covering analysts …

Oppenheimer Remains a Buy on Once Upon a Farm, PBC (OFRM)

Treace Medical Concepts, Inc. (TMCI) Stock Price, News, Quote & History

This page provides a comprehensive overview of Treace Medical Concepts, Inc. (TMCI) stock, including its current price, after-hours trading, historical data, and key financial metrics. It also features company news, analyst ratings, and a detailed description of its medical devices and technologies, such as …